KRIBIOLISA™ Pembrolizumab (KEYTRUDA) ELISA

0-1000ng/ml

Colorimetric, 450nm

Enzyme Immunoassay for quantitative detection of Pembrolizumab in serum and plasma. Pembrolizumab is a humanized antibody used in cancer immunotherapy. It is a therapeutic antibody that binds to and blocks PD-1 located on lymphocytes. This receptor is generally responsible for preventing the immune system from attacking the body's own tissues; it is a so-called immune checkpoint. Many cancers make proteins that bind to PD-1, thus shutting down the ability of the body to kill the cancer on its own. Inhibiting PD1 on the lymphocytes prevents this, allowing the immune system to target and destroy cancer cells. Krishgen PK kits, developed using the innovator drug as calibrator, are used for the quantitation of serum protein drug levels, and can be used for biosimilar and generics research as well. About the kit: - Uses anti-idiotypic antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity. - Recovery rates are between 85 - 115% - Ready to use with a standard protocol with break-apart pre-coated wells - Validated as per US FDA guidelines for Bioassays - Optimized for matrix effects to ensure higher sensitivity. - Shelf life: 1 year The method employs the quantitative enzyme immunoassay technique. Standards or samples are pipetted into microwells pre-coated with Anti- Pembrolizumab antibody and Pembrolizumab present in the sample and standards are bound by Anti- Pembrolizumab antibody. In the second step, Detection antidody is added and incubated. In the third step, a HRP conjugate is pipetted and incubated. Free HRP conjugate will be removed by washing. Addition of TMB substrate will develop blue color and intensity of blue colour in wells is proportional to the concentration of Pembrolizumab present in standard or sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.

Serum and Plasma

80ng/ml